
MiNK Therapeutics (INKT) Stock Forecast & Price Target
MiNK Therapeutics (INKT) Analyst Ratings
Bulls say
MiNK Therapeutics Inc. has experienced a significant increase in its stock price, with shares rising over 400% in the past week, indicating strong investor enthusiasm compared to a mere 2% increase in the Nasdaq Biotechnology Index (NBI). The company's innovative approach to iNKT cell therapies offers scalable and cost-effective manufacturing processes, which enhance its potential for widespread use in treating cancer and other immune-mediated diseases. Further positive momentum is anticipated as updates from the Phase 2 gastric trial of agenT-797, expected in late 2025 or early 2026, could provide critical efficacy data that may influence future evaluations of the company’s growth prospects.
Bears say
MiNK Therapeutics Inc faces significant risks that may adversely affect its financial outlook, including potential safety signals and lower-than-expected efficacy from its clinical programs, which could hinder the advancement of its therapies. Additionally, the company may encounter heightened commercial competition and regulatory challenges, further complicating its path to market. Financially, MiNK requires about $55 million in additional financing through 2038, with a limited cash runway extending only into mid-2025, raising concerns about its funding and operational stability.
This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction
Start investing in MiNK Therapeutics (INKT)
Order type
Buy in
Order amount
Est. shares
0 shares